Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David W Dodick

Showing results (261-270 of 365) with videos related to

Pageof 37
Sort By:
Cephalalgia : an International Journal of Headache|November 26, 2020
Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implicationsPeter J Goadsby, Andrew M Blumenfeld, Richard B Lipton, et al.
The New England Journal of Medicine|November 25, 2017
Fremanezumab for the Preventive Treatment of Chronic MigraineStephen D Silberstein, David W Dodick, Marcelo E Bigal, et al.
The Lancet. Neurology|October 4, 2015
Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b studyMarcelo E Bigal, David W Dodick, Alan M Rapoport, et al.
Nature Medicine|May 12, 2025
Ubrogepant for the treatment of migraine prodromal symptoms: an exploratory analysis from the randomized phase 3 PRODROME trialPeter J Goadsby, Jessica Ailani, David W Dodick, et al.
Cephalalgia : an International Journal of Headache|November 2, 2020
Characterization and preclinical evaluation of a protease activated receptor 2 (PAR2) monoclonal antibody as a preventive therapy for migraineCaroline M Kopruszinski, Peter Thornton, Joanne Arnold, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|March 29, 2014
Association of ischemic stroke, hormone therapy, and right to left shunt in postmenopausal womenNancy C Greep, David S Liebeskind, Rubine Gevorgyan, et al.
Headache|June 14, 2023
Long-term efficacy and safety of erenumab in patients with chronic migraine and acute medication overuse: A subgroup analysisStewart J Tepper, Richard B Lipton, Stephen D Silberstein, et al.
Neurology|May 3, 2015
Milestone-compatible neurology resident assessments: A role for observable practice activitiesLyell K Jones, Elliot L Dimberg, Christopher J Boes, et al.
The Lancet. Neurology|March 9, 2010
Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a randomised, double-blind, parallel-group, sham-controlled trialRichard B Lipton, David W Dodick, Stephen D Silberstein, et al.
Cephalalgia : an International Journal of Headache|March 27, 2023
Diagnosis, knowledge, perception, and productivity impact of headache education and clinical evaluation program in the workplace at an information technology company of more than 70,000 employeesFumihiko Sakai, Hisaka Igarashi, Masako Yokoyama, et al.
Pageof 37

Showing results (261-270 of 365) with videos related to

Sort By:
Pageof 37
Cephalalgia : an International Journal of Headache|November 26, 2020
Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implicationsPeter J Goadsby, Andrew M Blumenfeld, Richard B Lipton, et al.
The New England Journal of Medicine|November 25, 2017
Fremanezumab for the Preventive Treatment of Chronic MigraineStephen D Silberstein, David W Dodick, Marcelo E Bigal, et al.
The Lancet. Neurology|October 4, 2015
Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b studyMarcelo E Bigal, David W Dodick, Alan M Rapoport, et al.
Nature Medicine|May 12, 2025
Ubrogepant for the treatment of migraine prodromal symptoms: an exploratory analysis from the randomized phase 3 PRODROME trialPeter J Goadsby, Jessica Ailani, David W Dodick, et al.
Cephalalgia : an International Journal of Headache|November 2, 2020
Characterization and preclinical evaluation of a protease activated receptor 2 (PAR2) monoclonal antibody as a preventive therapy for migraineCaroline M Kopruszinski, Peter Thornton, Joanne Arnold, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|March 29, 2014
Association of ischemic stroke, hormone therapy, and right to left shunt in postmenopausal womenNancy C Greep, David S Liebeskind, Rubine Gevorgyan, et al.
Headache|June 14, 2023
Long-term efficacy and safety of erenumab in patients with chronic migraine and acute medication overuse: A subgroup analysisStewart J Tepper, Richard B Lipton, Stephen D Silberstein, et al.
Neurology|May 3, 2015
Milestone-compatible neurology resident assessments: A role for observable practice activitiesLyell K Jones, Elliot L Dimberg, Christopher J Boes, et al.
The Lancet. Neurology|March 9, 2010
Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a randomised, double-blind, parallel-group, sham-controlled trialRichard B Lipton, David W Dodick, Stephen D Silberstein, et al.
Cephalalgia : an International Journal of Headache|March 27, 2023
Diagnosis, knowledge, perception, and productivity impact of headache education and clinical evaluation program in the workplace at an information technology company of more than 70,000 employeesFumihiko Sakai, Hisaka Igarashi, Masako Yokoyama, et al.
Pageof 37